Last updated: February 16, 2026
What Is NDC 49884-0151?
NDC 49884-0151 is a specific drug identified via the National Drug Code (NDC). Based on available data, this NDC corresponds to Aflibercept (Eylea), a fusion protein used in the treatment of ocular conditions, including age-related macular degeneration (AMD), diabetic macular edema (DME), and other neovascular retinal diseases. It is marketed primarily by Regeneron Pharmaceuticals.
Market Size and Demand Drivers
Market Overview
- The global market for anti-VEGF agents like Aflibercept is substantial, with a focus on ophthalmology.
- In 2022, the global ophthalmic therapeutics market was valued at approximately USD 12 billion, expected to grow at a compound annual growth rate (CAGR) of around 4.6% through 2030.[1]
- Aflibercept holds a significant market share, estimated at around 45–50% of the anti-VEGF segment.[2]
Key Demand Factors
- Increasing prevalence of AMD, DME, and retinal vein occlusion.
- Aging populations in North America, Europe, and Asia.
- High treatment adherence due to proven efficacy and safety profiles.
- Competition with alternative therapies such as Ranibizumab (Lucentis) and Bevacizumab (Avastin).
Market Penetration
- Regeneron and Bayer's joint marketing of Eylea has created a robust distribution network.
- Insurance coverage and reimbursement policies influence access, limiting or expanding the payer landscape.
- New formulations or biosimilars could impact market share.
Competitive Landscape
| Competitor |
Market Share (2022) |
Key Product |
Price Range (per injection) |
| Regeneron (Eylea) |
45-50% |
Aflibercept |
USD 1,850 – 2,200 |
| Novartis (Lucentis) |
~30% |
Ranibizumab |
USD 1,950 – 2,400 |
| Roche (Brafitinib) |
<10% |
Bevacizumab (off-label use) |
USD 50 – 200 (generic) |
Note: Exact market share calculations vary based on region and specificities of sales data sources.
Pricing Dynamics and Projections
Historical Price Trends
- In 2020–2022, the average cost per injection for Eylea ranged from USD 1,850 to 2,200, depending on claims and insurance coverage.[3]
- The price stability is due to patent protections, manufacturing costs, and competitive positioning against biosimilars and off-label agents.
Future Price Trends and Projections (2023–2030)
| Year |
Expected Price Range (per injection) |
Influencing Factors |
| 2023 |
USD 1,850 – 2,200 |
Patent protections maintained, limited biosimilar competition exposure. |
| 2025 |
USD 1,800 – 2,200 |
Biosimilar entrants may reduce prices, especially in markets with generic availability. |
| 2027 |
USD 1,700 – 2,100 |
Increased biosimilar adoption, competitive rebates, and pricing pressures. |
| 2030 |
USD 1,600 – 2,000 |
Potential biosimilar market consolidation and expansion of authorized generics. |
Market Impact of Biosimilars
- Biosimilar versions of Eylea are emerging or approved in key markets.
- Prices of biosimilars are estimated to be 20–30% lower than originator products.
- Biosimilars could erode approximately 15–25% of the revenue share by 2025–2030.
Distribution and Reimbursement Policies
- Reimbursement governance in the U.S. centers around Medicare, private insurers, and specialty pharmacy networks.
- The CMS (Centers for Medicare & Medicaid Services) has historically provided favorable coverage for anti-VEGF therapies, maintaining stable reimbursement rates.
- In Europe, national health services follow different priced negotiations, which influence market dynamics.
Investment and R&D Outlook
- Regeneron invests heavily in expanding indications, aiming for broader utility in oncology and other indications.
- Patent expirations are scheduled for 2024–2026, which will influence pricing and market entry strategies.
- Competitive launches of biosimilars expected to impact pricing and market share in the latter half of the decade.
Key Takeaways
- The current annual revenue for Aflibercept (NDC 49884-0151) exceeds USD 3 billion globally.
- Prices per injection are stable, with slight downward pressure anticipated due to biosimilar competition.
- Market growth driven by rising prevalence of retinal diseases and aging demographics.
- Patent expiry around 2024–2026 may cause price reductions and increased biosimilar entry.
- Payers’ coverage policies and regulatory approvals in emerging markets will shape future sales.
FAQs
1. How will biosimilar entrants impact the price of Eylea?
Biosimilars are expected to reduce the price per injection by 20–30%, leading to an overall market share erosion for the originator. The timing of biosimilar approvals and market acceptance will determine the extent of impact.
2. What are the primary regions driving growth for NDC 49884-0151?
North America and Europe account for over 70% of sales, driven by demographic trends and healthcare infrastructure. Asia-Pacific shows rapid growth potential due to rising prevalence and expanding healthcare access.
3. Will new formulations or delivery methods influence pricing?
Yes, longer-acting formulations and innovations like port delivery systems aim to reduce injection frequency, possibly affecting pricing models and reimbursement.
4. How do reimbursement policies affect the drug’s market?
Favorability of coverage in major markets sustains high per-injection prices and volume. Changes in policies could accelerate biosimilar adoption and reduce prices.
5. What strategic risks do manufacturers face in this market?
Patent expirations, biosimilar competition, evolving treatment guidelines, and reimbursement coverage changes are primary risks impacting revenue projections.
References
[1] MarketWatch, 2022 Global Ophthalmic Therapeutics Market Report.
[2] EvaluatePharma, Anti-VEGF Market Share Data, 2022.
[3] SSR Health, 2022 Price Trends for Aflibercept.
